In Memory of Dana Lynn Siegel

The BCA lost one of our dear friends a few months ago. Dana Lynn Siegel passed away in November 2010 at the age of 65.

Dana will be remembered for her positive spirit, boundless energy and warm smile. Dana assisted the BCA by serving on the Board of Directors, as a committee member for the  annual survivorship celebration, and was instrumental in reviving the Breast Cancer Alliance's Wall of Hope. This photo of Dana was featured on the Wall of Hope. The photo included the following quote, "I did not have control over what was happening to me, but I did have control over how I let it affect my life."

A wonderful article was written about Dana in Cincy Chic last September. This article really sums up what a strong woman Dana was.

Click here to read that article:

Back to Top

Please join the BCA at these Upcoming Events:

Saturday, February 12, 2011 at Molloy's on the Green 7:00pm-midnight for an evening of fun that will benefit the BCA. Bands scheduled to appear: Judging Smails and Gil's Variety Store.

Cost $10.00 per person.

Saturday, February 26, 2011 at 7:00pm Sing for a Cause. The choirs from three area high schools (Taylor, Sycamore and Lakota) will put on a benefit concert at the Good Shepherd Lutheran Church in Kenwood.

All proceeds from ticket sales will go towards the BCA and a local Alzheimer's group. Tickets will cost $10 for adults and $5 for students.

Saturday, April 2, 2011 a follow up conversation with Dr. Cathy Rosenbaum of Rx Integrative Solutions on the Seven Balance Points of Health. This forum will be held at the Wellness Community in Blue Ash from 10:00-11:00am.

For more information about these events and other happenings in our community visit: www.bcacincy.org  or call: 513-530-0545

Hot Topics:

Last month, the Food and Drug Administration (FDA) notified healthcare professionals and patients that it is recommending removing the breast cancer indication for Avastin (bevacizumab) because the drug has not been shown to be safe and effective for that use.

The FDA has made this decision after reviewing the results of four clinical studies of Avastin in women with breast cancer that show no improvement in overall survival and insufficient benefit in slowing disease progression to outweigh the significant risks to patients.  

The drug itself is not being removed from the market and this action will not have any immediate impact on its use in treating breast cancer. This action by the FDA will not affect the approvals for colon, kidney, brain, and lung cancers.

To read more about this decision click

here.

Click here to read Cure Magazine's Progress and Promise in Breast Cancer (Winter Supplement) which covers advancements in radiation, drug therapy, surgery and clinical trials."